Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Dose Escalation Study of BMS-823778 in Healthy Subjects and Patients with Type 2 Diabetes Mellitus
jRCT2080221729Phase 1
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing BMS-823778 with Placebo (2 arms). Primary endpoints: Safety of BMS-823778, Pharmacokinetics of BMS-823778 and 1 more.
02
Drugs
bms-823778
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080221729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221729.